Contribute Try STAT+ Today

Hoping to boost confidence in its Repatha cholesterol drug, Amgen said the treatment significantly reduced the risk of heart attacks, strokes, and death in patients with heart disease in a closely watched clinical trial. But the biotech did not disclose any data to demonstrate the extent to which the medicine reduced these cardiovascular risks.

Complete details will not become available until an American College of Cardiology meeting next month. But by declaring now that Repatha met the primary endpoint in the study, Amgen hopes to persuade payers to provide greater coverage for the pricey medicine. About 75 percent of prescriptions have reportedly been rejected due to the $14,000 list price and the lack of cardiovascular outcomes data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.